Navigation Links
Penn study suggests another avenue for detecting Alzheimer's disease
Date:4/1/2011

PHILADELPHIA Researchers at the University of Pennsylvania School of Medicine have determined that a well-known chemical process called acetylation has a previously unrecognized association with one of the biological processes associated with Alzheimer's disease and related disorders. The findings were published in the latest issue of Nature Communications.

Tau is one of the primary disease proteins associated with a suite of neurodegenerative diseases. Tau proteins are expressed primarily in the central nervous system where they help with the assembly and stability of microtubules, protein structures that are the backbone of the nerve-cell communication system.

"Acetylation was only detected in diseased brain tissue from patients with Alzheimer's disease or frontotemporal degeneration, suggesting it may have a role in tau transformation linked to disease onset and progression," says senior author Virginia M.-Y. Lee, PhD, director of Penn's Center for Neurodegenerative Disease Research. "This suggests that one type of acetylation is a potential target for drug discovery and biomarker development for Alzheimer's and related tauopathies."

The researchers demonstrated that tau acetylation led to a loss of one of its major functions - to promote microtubule assembly, in addition to gaining a toxic function, pathological tau aggregation. Mass spectrometry analysis identified specific acetylation sites in the tau protein sequence that overlapped with known microtubule binding sequences, so acetylation may also play a role in faulty binding of tau to microtubules.

How normal tau becomes disengaged from microtubules to form disease-related clumps remains unknown. This study shows that acetylation is most likely another chemical modification implicated in neurodegenerative disorders to be explored as a potential way to detect and fight brain disease.

According to Lee, the next steps to follow up on this discovery are to pursue basic research into the mechanisms underlying this pathological acetylation of tau and its role in neurodegeneration in Alzheimer's disease and related tauopathies. In addition, she noted that "Our highest priority will be to find ways to translate these findings into better diagnostics and therapeutics for patients with Alzheimer's disease or frontotemporal degeneration."


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert  

Related medicine news :

1. Many Moms Have Kids With Different Dads, U.S. Study Finds
2. Surprising finding from smoke inhalation study
3. Prostate Cancer Screening Doesnt Cut Death Rates: Study
4. New lung cancer staging system (TNM 7) better predicts local/regional recurrence, study shows
5. Soy increases radiations ability to kill lung cancer cells, study shows
6. Moms With Tough Childhoods More Likely to Have Smaller Babies: Study
7. For Young Kids With Pneumonia, Timing of Antibiotic Critical: Study
8. Pilot study examines stress, anxiety and needs of young women with a unique breast cancer
9. Case Western Reserve receives $1.6M to study tumor cells and immune cell detection
10. STUDY: 3 square meals a day paired with lean protein help people feel full during weight loss
11. Antibacterial Soap Additive Accumulates in Fish: Study
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Penn study suggests another avenue for detecting Alzheimer's disease
(Date:4/29/2016)... Pass, OR (PRWEB) , ... April 29, 2016 , ... ... suggest dinner as the meal to miss. That was among the many new lifestyle ... Nutrition, on a recent Sharon Kleyne Hour® Power of Water® radio show. Bonny and ...
(Date:4/29/2016)... ... , ... The infertility specialists at HRC Fertility/Orange County (HRC/OC) -- Dr. Mickey ... -- are proud of the recent release of their 2014 in vitro fertilization success ... published the latest verified data for 375 U.S. member clinics. *Preliminary data shows HRC/OC ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... raising awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in ... efficacy of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The ... adding BC and AD, saying it is time to set the record straight. Traditionally, ... says this simply cannot possibly be true and offers explanation. , “To start with, ...
(Date:4/28/2016)... ... April 29, 2016 , ... Sublime Beauty® is offering a special deal on its webstore. ... off. The discount is applied to the product with lesser value. In addition, a ... purchase $250 or more in products. , "So many women (men, too) love our products ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 Oasmia Pharmaceutical ... of a new generation of drugs within human ... results for Paclical/Apealea in the Phase III study ... epithelial ovarian cancer. These preliminary results showed non-inferiority ... with carboplatin versus Taxol in combination with carboplatin. ...
(Date:4/27/2016)... At the Sachs CEO forum ... Phase 2 clinical study of its lead drug candidate, ... implantation (CI) surgery. This large, placebo-controlled, double-blind, phase 2 ... and France . STR001 ... time of surgery. "Despite advances in cochlear implant technology, ...
(Date:4/26/2016)... 2016 US demand for infection prevention ... percent annually to $27.6 billion in 2020.  Increasing ... decrease rates of healthcare-associated infections (HAIs) will boost ... services.  Although declining, the overall rate of certain ... set by the CDC.  Recent statistics indicate that ...
Breaking Medicine Technology: